ArticleVirology journal2025
Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of week-12 HBsAg Decline with HBsAg Clearance in Patients with Hepatitis B-Related Cirrhosis Receiving Pegylated Interferon Combined with Nucleos(T)ide Analogue Therapy: A Retrospective Cohort Study.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposeTo identify early predictive factors for hepatitis B surface antigen (HBsAg) clearance at week 48 following pegylated interferon (Peg-IFN) therapy in inactive HBsAg carriers (IHC), and to develop an early machine learning-based model to assist clinical decision-making.
methodsThis retrospective analysis was based on a multicenter, prospective cohort and included 777 IHC patients who received at least 48 weeks of Peg-IFN therapy. Least Absolute Shrinkage and Selection Operator (LASSO) regression and the Boruta algorithm were applied to select predictive variables. Nine machine learning models-including logistic regression (LR), decision tree (DT), and random forest (RF)-were constructed and evaluated using 10-fold cross-validation. An external validation cohort (n = 167) from three medical centers in Beijing was used for model validation. SHapley Additive exPlanations (SHAP) values were used to interpret variable contributions.
resultsThe overall HBsAg clearance rate at week 48 was 29.9% (232/777). Key predictors included baseline HBsAg level, HBsAg decline > 1 log IU/mL at week 12, and the ratio of alanine aminotransferase (ALT) to HBsAg at week 12. The RF model demonstrated the best performance with an area under the curve (AUC) of 0.829 (95% CI: 0.784-0.874) and specificity of 0.774 in the training set, and an AUC of 0.838 (95% CI: 0.759-0.917) with specificity of 0.968 in the external validation set. SHAP analysis showed that baseline HBsAg had the highest predictive importance.
conclusionsThe RF-based model accurately predicts HBsAg clearance in IHC patients undergoing Peg-IFN therapy and offers a promising tool for early identification of candidates for individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.